# Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products, Division A.2: Development of resistance

Extent: E+W+S+N.I.

Where relevant, data on the potential emergence of resistant organisms of clinical relevance are necessary for veterinary medicinal products. The mechanism of the development of such resistance is particularly important in this regard. Measures to limit resistance development from the intended use of the veterinary medicinal product shall be proposed by the applicant.
Where relevant, cross reference shall be made to data set out in Part 3.

---
Source: https://www.legislation.gov.uk/eudr/2001/82/annex/I/title/I/part/4/chapter/I/division/A/division/A.2 (the official version)
Page: https://openlegislation.uk/eu-directive-2001-82/annex-I/title-I/part-4/chapter-I/division-A/division-A.2
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.